Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Disease Spotlight

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Videos

Neurology News Network. for the week ending May 18, 2024. [WATCH TIME: 4 minutes]

Dosing Commenced in Study of Anti-Tau Agent, FDA Updates Labeling to Glatiramer Acetate Products, Eisai Initiates Rolling Submission for Subcutaneous Lecanemab 

Articles

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 17, 2024. 

NeurologyLive® Friday 5 — May 17, 2024

A panel of experts provided a new update on practice guidelines for prescribing antiseizure medications to patients with epilepsy who may have a pregnancy.

New Published Guidelines Issued for Antiseizure Medications in Patients Seeking Pregnancy

Voyager expects insights from the phase 1a study to inform a subsequent phase 1b trial and anticipates tau PET imaging data in 2026.

Dosing Commenced for Phase 1a Study of Anti-Tau Antibody VY-TAU01 in Alzheimer Disease

The associate professor of neurology at Harvard Medical School talked about findings from a recent case series of patients with NMOSD initially on rituximab who then switched to inebilizumab. [WATCH TIME: 4 minutes]

Efficacy of Switching From to Inebilizumab in Rituximab in NMOSD: Michael Levy, MD, PhD

, has been with the team since October 2019. Follow him on Twitter 

Mayo's MOGAD Clinic represents a new type of novel, multidisciplinary care, incorporating multiple different backgrounds of neurology, neuroimmunology, neuro—ophthalmology, and urology, among others.

Building the Archetype for MOGAD Care: Introducing Mayo’s New Clinic

The Consortium of Multiple Sclerosis Centers' 38th Annual Meeting will be held Wednesday, May 29, through Saturday, June 1, 2024 at the Music City Center, in Nashville, Tennessee.

CMSC 2024: What to Expect From This Year's Annual Meeting

Cure SMA introduces tools aiding in SMA clinical trial navigation and participation empowerment.

Cure SMA Unveils Initiatives to Improve Clinical Trial Accessibility

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

Twitter

LinkedIN

YouTube

Spotlight

AAN 2024

MDA 2024

ACTRIMS 2024

Treating NMOSD: What's Next?

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

1rem

View

AAN 2020: Multiple Sclerosis Treatment Considerations

Multiple Sclerosis and Risk of COVID-19

Disease-Modifying Therapies for MS During COVID-19

AAN 2020: Real-World Data on Cladribine Tablets for MS

Multiple Sclerosis: Takeaways From AAN 2020

MS Treatment Optimization During COVID-19

Treating Patients With MS During the COVID-19 Pandemic

AAN 2020 Data Release: Ofatumumab for Relapsing MS

Novel Oral Therapy for MS: AAN Data Updates

The Future of Multiple Sclerosis Management

Clinical

EMD-22-NRD0193 - /clinical/multiple-sclerosis

The News Network video series features a variety of clinicians providing updates on the major data and paradigm-affecting updates from societal meetings and conferences focused on patients with neurologic diseases.